Clinical trials
Metastatic Hormone Receptor-Positive Breast Carcinoma clinical trials
Below are recruiting metastatic hormone receptor-positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT07369505RecruitingPhase 1
A study of Sapu003 for advanced tumors sensitive to mTOR
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
AdelaideAges 18 years+ - NCT04400695RecruitingPhase 3
Targeted drug for breast cancer with low HER2 levels
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
Beijing, Beijing MunicipalityAges 18–70 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+
Hear when a new Metastatic Hormone Receptor-Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic hormone receptor-positive breast carcinoma?
- Yes. Clin2 currently lists 32 recruiting metastatic hormone receptor-positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic hormone receptor-positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic hormone receptor-positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone Receptor Positive Breast Carcinoma
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Estrogen Receptor-Positive Breast Carcinoma
- Hormone Receptor Negative Breast Carcinoma
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Metastatic Breast Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.